News from prometheus laboratories inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 31, 2014, 08:00 ET

PROCLAIM(SM) National Patient Registry Analysis Shows Improved Median Overall Survival in Patients with Metastatic Melanoma Treated with High-Dose Interleukin-2 (HD IL-2)

 Prometheus Laboratories Inc. announced today that data from the PROCLAIMSM national patient registry retrospective cohort document an...

May 30, 2014, 08:00 ET

PROCLAIM(SM) Patient Registry Data Show Extension of Overall Survival Benefits Beyond Complete and Partial Responders in Metastatic Renal Cell Carcinoma Patients Treated with High-Dose Interleukin-2 (HD IL-2)

 Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIMSM national patient registry retrospective cohort shows...

Oct 10, 2013, 09:15 ET

Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin?2 in SITC Guidelines for Treatment of Cutaneous Melanoma

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces the inclusion of Proleukin® (aldesleukin for...

Sep 19, 2013, 09:00 ET

Prometheus Laboratories Appoints Chief Executive Officer

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company announced today that Ms. Lisa Miller has been appointed to the...

May 30, 2013, 09:20 ET

Prometheus Laboratories Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients with Metastatic Melanoma

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY02, a multi-center study comparing the...

May 22, 2013, 16:32 ET

Prometheus Laboratories Presents New Data On Growing IBD Diagnostic Portfolio At Digestive Disease Week 2013

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the eighteen abstracts relating to its proprietary...

May 09, 2013, 12:46 ET

Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY 01, a multi-center...

Apr 30, 2013, 09:00 ET

Prometheus Launches New Adalimumab Drug And Antibody Levels Monitoring Test

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the US market launch of its proprietary new test,...

Oct 22, 2012, 09:00 ET

New Data Support Use Of PROMETHEUS® Anser™ IFX Assay In Managing infliximab Treatment Failure Among Inflammatory Bowel Disease Patients

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, will present five abstracts at the American College of...

Jul 31, 2012, 09:10 ET

Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new...

May 22, 2012, 11:15 ET

New Data Support Role of Prometheus Laboratories' Novel Assay in Optimizing IBD Treatment Management

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the thirteen abstracts relating to its...

Feb 07, 2012, 09:10 ET

Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research and...

Feb 03, 2012, 09:10 ET

Prometheus Announces New Chief Commercial Officer

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Anthony J. Yost as Senior...

Nov 14, 2011, 11:19 ET

Prometheus Announces New Chief Medical Officer

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Peter Heseltine as Senior...

Oct 24, 2011, 08:00 ET

Prometheus Launches Next Generation IBD Diagnostic Test

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary...

May 24, 2011, 01:30 ET

Prometheus Announces Agreement to be Acquired by Nestle Health Science

Prometheus Laboratories Inc., ("Prometheus") a specialty pharmaceutical and diagnostic company, today announced that it has entered into a...

May 02, 2011, 06:00 ET

Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has signed an exclusive agreement with...

Mar 01, 2011, 09:00 ET

Prometheus Highlights Record Performance in 2010

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development...

Feb 22, 2011, 18:00 ET

Prometheus Receives New York State Approval for PROMETHEUS® Crohn's Prognostic, the First Serogenetic Test to Predict Risk of Complications From Crohn's Disease

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has received New York State approval for...

Dec 09, 2010, 17:43 ET

Prometheus Laboratories and UCLA Sign Agreement to Validate Biological Markers of Mucosal Healing in IBD

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles...